Mahajan, AnnilSharma, RashmiKhajuria, RuchiBardi, Ghulam HussainKapoor, BhuvneshwarGupta, Vijay2006-06-252009-05-312006-06-252009-05-312006-06-25Mahajan A, Sharma R, Khajuria R, Bardi GH, Kapoor B, Gupta V. Rheumatoid arthritis: new developments in biologic therapy. Journal of the Indian Medical Association. 2006 Jun; 104(6): 327-30http://imsear.searo.who.int/handle/123456789/97151With the development of biologic agents our therapeutic approach to rheumatoid arthritis (RA) and inflammatory diseases in general, has dramatically changed within the last few years. Biologic technically means a substance as the product of biologic system and functionally as an agent that targets specific biologic molecule. Recently a number of endogenous antigens have been identified and these are known to activate CD4+ T cells leading to production of cytokines [interleukin (IL)-1, IL-6] and tumour necrosis factor (TNF)-alpha and immunoglobulins like rheumatoid factor and expression of osteoprotegerin ligands that stimulate osteogenesis leading to joint distruction. Rheumatologists and other practitioners are facing a remarkable wave of new therapies for RA like infliximab, adalimumab, atlizumab, etanercept, anakinra, prosorbacolumn, anti-IL-6 agents, IL-10 and inferferon-r. To date combination therapy of methotrexate plus a single biologic has been widely studied with synergistic effect. Etanercept and infliximab are two biologics available in India.engAntibodies, Monoclonal --therapeutic useArthritis, Rheumatoid --immunologyBiological Therapy --trendsHumansImmunoglobulin G --therapeutic useInterleukin-1Interleukin-10Receptors, Tumor Necrosis Factor --therapeutic useTumor Necrosis Factor-alphaJournal Article